40153-45-5

Upstream product

• 7664-93-9 sulfuric acid 
• 6272-18-0 N-(5,6,7,8-tetrahydronaphthalen-1-yl)acetamide 
• 7697-37-2 nitric acid 
• 2217-41-6 1-amino-5,6,7,8-tetrahydronaphthalene 
• 29809-14-1 5-nitro-1,2,3,4-tetrahydronaphthalene 
• 90-15-3 α-naphthol 
• 119-64-2 tetralin 
• 50537-01-4 4-nitro-5,6,7,8-tetrahydro-[1]naphthylamine 
• 108-24-7 acetic anhydride 

Relevant academic research and scientific papers

THERAPEUTIC B7-H4 BINDING MOLECULES

The present invention relates to binding molecules (e.g. antibodies) for the treatment of cancer, and related antibody-drug conjugates.

COMPOUNDS AND CONJUGATES THEREOF

A conjugate comprising the following topoisomerase inhibitor derivative (A*): where Y is H or F, with a single overall linker moiety connecting two topoisomerase inhibitor derivatives to a Ligand Unit, wherein the topoisomerase inhibitor derivatives are cleavable from the Ligand Unit. Also provided is A* with the linking unit attached, and intermediates for their synthesis.

COMPOUNDS AND CONJUGATES THEREOF

A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.

Congo red analogues as potential anti-prion agents

'Transmissible Spongiform Encephalopathies' (TSE) are a group of degenerative, progressive and fatal disorders of CNS which affect both humans and animals, characterised by a long incubation time. The pathogenetic mechanism in TSE is the conversion of normal prion protein (PrPsen) to an altered protease resistant isoform (PrPres) that accumulates in amyloid deposits into the brain; therefore, PrPres is the primary target for therapeutic strategies. The discovery that the sulphonated azo dye Congo red (CR) is able to inhibit the replications of TSE agents and the accumulation of PrPres in animals and in scrapie infected mouse neuroblastoma cells induced us to designe molecules structurally related to CR (1a-f, 2f,g). The compounds were tested in vitro to evaluate their interaction with 263K PrPres. Six of the tested compounds were found to interact with PrPres molecules and to over-stabilise the PrPres aggregates, as CR does. However, none of them induced the reversion of PrP res to PrPsen.

Substituted 2-arylimino heterocycles and compositions containing them, for use as progesterone receptor binding agents

This invention relates to 2-arylimino heterocycles, including 2-arylimino-1,3-thiazolidines, 2-arylimino-2,3,4,5-tetrahydro-1,3-thiazines, 2-arylimino-1,3-thiazolidin-4-ones, 2-arylimino-1,3-thiazolidin-5-ones, and 2-arylimino-1,3-oxazolidines, and their use in modulating progesterone receptor mediated processes, and pharmaceutical compositions for use in such therapies.